<p>在当前市场交易中，<strong>再生元制药公司 (NASDAQ: REGN)</strong> 的股价为 $780.00，下降幅度为 <strong>0.95%</strong>。然而，在过去一个月中，该公司的股价上涨了 <strong>1.61%</strong>，在过去一年中上涨了 <strong>12.75%</strong>。股东可能会想知道该股票是否被高估，即使公司在当前交易中的表现不尽如人意。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="过去一年图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_0.png"/></p>
<h3>比较再生元制药的市盈率与同行</h3>
<p>市盈率是长期股东用来评估公司市场表现的指标，通常与整体市场数据、历史收益和行业整体情况进行比较。较低的市盈率可能表明股东不期望该股票在未来表现更好，或者可能意味着公司被低估。</p>
<p>与生物技术行业的整体市盈率 <strong>76.09</strong> 相比，再生元制药公司的市盈率为 <strong>18.48</strong>，较低。股东可能倾向于认为该股票的表现可能不如行业同行。也有可能该股票被低估。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="仪表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_1.png"/></p>
<p>总之，市盈率是分析公司市场表现的有用指标，但它也有其局限性。虽然较低的市盈率可能表明公司被低估，但它也可能暗示股东不期望未来增长。此外，市盈率不应单独使用，因为行业趋势和商业周期等其他因素也会影响公司的股价。因此，投资者应将市盈率与其他财务指标和定性分析结合使用，以做出明智的投资决策。</p>

再生元制药

动态生物技术与基因组 ETF - Invesco

IBBQ

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

<p>再生元制药（Regeneron Pharmaceuticals Inc.，NASDAQ:REGN）股票目前价格为 780.00 美元，反映出下跌 0.95%。在过去一个月中，该股票上涨了 1.61%，在过去一年中上涨了 12.75%。公司的市盈率为 18.48，显著低于生物技术行业平均水平 76.09，这表明可能存在被低估或较低的增长预期。建议投资者在做出明智决策时，考虑市盈率与其他财务指标和定性因素的结合</p>

<p>In the current market session, <strong>Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)</strong> stock price is at $780.00, after a <strong>0.95%</strong> drop. However, over the past month, the company's stock spiked by <strong>1.61%</strong>, and in the past year, by <strong>12.75%</strong>. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.</p>
<div class="lb-trans"><p>在当前市场交易中，<strong>再生元制药公司 (NASDAQ: REGN)</strong> 的股价为 $780.00，下降幅度为 <strong>0.95%</strong>。然而，在过去一个月中，该公司的股价上涨了 <strong>1.61%</strong>，在过去一年中上涨了 <strong>12.75%</strong>。股东可能会想知道该股票是否被高估，即使公司在当前交易中的表现不尽如人意。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_0.png" alt="Past Year Chart" original-src="https://www.benzinga.com/files/images/story/2026/1772661628_0.png"/></p>
<h3>Comparing Regeneron Pharmaceuticals P/E Against Its Peers</h3>
<div class="lb-trans"><h3>比较再生元制药的市盈率与同行</h3>
</div><p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued.</p>
<div class="lb-trans"><p>市盈率是长期股东用来评估公司市场表现的指标，通常与整体市场数据、历史收益和行业整体情况进行比较。较低的市盈率可能表明股东不期望该股票在未来表现更好，或者可能意味着公司被低估。</p>
</div><p>Compared to the aggregate P/E ratio of the <strong>76.09</strong> in the Biotechnology industry, Regeneron Pharmaceuticals Inc. has a lower P/E ratio of <strong>18.48</strong>. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued.</p>
<div class="lb-trans"><p>与生物技术行业的整体市盈率 <strong>76.09</strong> 相比，再生元制药公司的市盈率为 <strong>18.48</strong>，较低。股东可能倾向于认为该股票的表现可能不如行业同行。也有可能该股票被低估。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_1.png" alt="Guage" original-src="https://www.benzinga.com/files/images/story/2026/1772661628_1.png"/></p>
<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.</p>
<div class="lb-trans"><p>总之，市盈率是分析公司市场表现的有用指标，但它也有其局限性。虽然较低的市盈率可能表明公司被低估，但它也可能暗示股东不期望未来增长。此外，市盈率不应单独使用，因为行业趋势和商业周期等其他因素也会影响公司的股价。因此，投资者应将市盈率与其他财务指标和定性分析结合使用，以做出明智的投资决策。</p>
</div>

P/E Ratio Insights for Regeneron Pharmaceuticals

benzinga_article

Invesco Nasdaq Biotechnology ETF

再生元制药市盈率的深入分析